aTYR PHARMA INC Payments to Acquire Debt Securities, Available-for-sale
aTYR PHARMA INC (ATYR) reported Payments to Acquire Debt Securities, Available-for-sale of $13.85 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-07
- aTYR PHARMA INC payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $7.98M, a 56.06% decline year-over-year.
- aTYR PHARMA INC payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $5.87M, a 74.60% decline year-over-year.
- aTYR PHARMA INC payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $12.85M, a 50.72% decline year-over-year.
- aTYR PHARMA INC payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $39.34M, a 1252.35% increase year-over-year.
- aTYR PHARMA INC payments to acquire debt securities, available-for-sale for fiscal 2025 was $93.44M, a 35.23% increase from fiscal 2024.
- aTYR PHARMA INC payments to acquire debt securities, available-for-sale for fiscal 2024 was $69.10M, a 35.40% decline from fiscal 2023.
- aTYR PHARMA INC payments to acquire debt securities, available-for-sale for fiscal 2023 was $106.98M, a 153.99% increase from fiscal 2022.
- aTYR PHARMA INC payments to acquire debt securities, available-for-sale for fiscal 2022 was $42.12M, a 66.71% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $13.85M 10-Q · filed 2026-08-07 | $26.69M derived: sum of 3 quarters · filed 2026-08-07 | $66.03M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $5.87M 10-Q · filed 2026-05-15 | $18.71M derived: sum of 2 quarters · filed 2026-05-15 | $58.05M derived: sum of 3 quarters · filed 2026-05-15 | $76.21M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $12.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $52.19M derived: sum of 2 quarters · filed 2026-03-05 | $70.34M derived: sum of 3 quarters · filed 2026-08-07 | $93.44M 10-K · filed 2026-03-05 |
| 2025-09-30 | $39.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $57.49M derived: sum of 2 quarters · filed 2026-08-07 | $80.60M 10-Q · filed 2025-11-06 | $106.67M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $18.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $41.26M 10-Q · filed 2026-08-07 | $67.33M derived: sum of 3 quarters · filed 2026-08-07 | $70.24M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $23.11M 10-Q · filed 2026-05-15 | $49.17M derived: sum of 2 quarters · filed 2026-05-15 | $52.08M derived: sum of 3 quarters · filed 2026-05-15 | $70.87M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $26.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $28.98M derived: sum of 2 quarters · filed 2026-03-05 | $47.76M derived: sum of 3 quarters · filed 2026-03-05 | $69.10M 10-K · filed 2026-03-05 |
| 2024-09-30 | $2.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $21.70M derived: sum of 2 quarters · filed 2025-11-06 | $43.04M 10-Q · filed 2025-11-06 | $52.70M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $18.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $40.13M 10-Q · filed 2025-08-07 | $49.79M derived: sum of 3 quarters · filed 2026-03-05 | $78.40M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $21.34M 10-Q · filed 2025-05-07 | $31.00M derived: sum of 2 quarters · filed 2026-03-05 | $59.61M derived: sum of 3 quarters · filed 2026-03-05 | $82.09M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $9.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $38.27M derived: sum of 2 quarters · filed 2026-03-05 | $60.75M derived: sum of 3 quarters · filed 2026-03-05 | $106.98M 10-K · filed 2026-03-05 |
| 2023-09-30 | $28.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $51.09M derived: sum of 2 quarters · filed 2024-11-07 | $97.31M 10-Q · filed 2024-11-07 | $122.31M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $22.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $68.70M 10-Q · filed 2024-08-13 | $93.70M derived: sum of 3 quarters · filed 2025-03-13 | $99.64M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $46.23M 10-Q · filed 2024-05-02 | $71.22M derived: sum of 2 quarters · filed 2025-03-13 | $77.17M derived: sum of 3 quarters · filed 2025-03-13 | $88.34M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $24.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $30.94M derived: sum of 2 quarters · filed 2025-03-13 | $42.12M derived: sum of 3 quarters · filed 2025-03-13 | $42.12M 10-K · filed 2025-03-13 |
| 2022-09-30 | $5.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $17.12M derived: sum of 2 quarters · filed 2023-11-09 | $17.12M 10-Q · filed 2023-11-09 | $74.82M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $11.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $11.18M 10-Q · filed 2023-08-09 | $68.87M derived: sum of 3 quarters · filed 2024-03-14 | $97.66M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | $57.70M derived: sum of 2 quarters · filed 2024-03-14 | $86.48M derived: sum of 3 quarters · filed 2024-03-14 | $100.83M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $57.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $86.48M derived: sum of 2 quarters · filed 2024-03-14 | $100.83M derived: sum of 3 quarters · filed 2024-03-14 | $126.51M 10-K · filed 2024-03-14 |
| 2021-09-30 | $28.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $43.13M derived: sum of 2 quarters · filed 2022-11-14 | $68.81M 10-Q · filed 2022-11-14 | $69.71M derived: sum of 4 quarters · filed 2023-03-14 |
| 2021-06-30 | $14.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $40.02M 10-Q · filed 2022-08-15 | $40.92M derived: sum of 3 quarters · filed 2023-03-14 | $43.08M derived: sum of 4 quarters · filed 2023-03-14 |
| 2021-03-31 | $25.68M 10-Q · filed 2022-05-10 | $26.58M derived: sum of 2 quarters · filed 2023-03-14 | $28.73M derived: sum of 3 quarters · filed 2023-03-14 | $43.66M derived: sum of 4 quarters · filed 2023-03-14 |
| 2020-12-31 | $898.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $3.06M derived: sum of 2 quarters · filed 2023-03-14 | $17.98M derived: sum of 3 quarters · filed 2023-03-14 | $21.07M 10-K · filed 2023-03-14 |
| 2020-09-30 | $2.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $17.09M derived: sum of 2 quarters · filed 2021-11-12 | $20.17M 10-Q · filed 2021-11-12 | $26.15M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-06-30 | $14.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $18.01M 10-Q · filed 2021-08-11 | $23.99M derived: sum of 3 quarters · filed 2022-03-15 | $28.58M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-03-31 | $3.08M 10-Q · filed 2021-05-14 | $9.06M derived: sum of 2 quarters · filed 2022-03-15 | $13.65M derived: sum of 3 quarters · filed 2022-03-15 | $29.73M derived: sum of 4 quarters · filed 2022-03-15 |
| 2019-12-31 | $5.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $10.57M derived: sum of 2 quarters · filed 2022-03-15 | $26.65M derived: sum of 3 quarters · filed 2022-03-15 | $40.65M 10-K · filed 2022-03-15 |
| 2019-09-30 | $4.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $20.67M derived: sum of 2 quarters · filed 2020-11-13 | $34.67M 10-Q · filed 2020-11-13 | $51.59M derived: sum of 4 quarters · filed 2021-03-24 |
| 2019-06-30 | $16.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $30.08M 10-Q · filed 2020-08-13 | $47.00M derived: sum of 3 quarters · filed 2021-03-24 | $47.00M derived: sum of 4 quarters · filed 2021-03-24 |
| 2019-03-31 | $13.99M 10-Q · filed 2020-05-12 | $30.92M derived: sum of 2 quarters · filed 2021-03-24 | $30.92M derived: sum of 3 quarters · filed 2021-03-24 | $46.31M derived: sum of 4 quarters · filed 2021-03-24 |
| 2018-12-31 | $16.92M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $16.92M derived: sum of 2 quarters · filed 2021-03-24 | $32.31M derived: sum of 3 quarters · filed 2021-03-24 | $40.30M 10-K · filed 2021-03-24 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $15.39M derived: sum of 2 quarters · filed 2019-11-14 | $23.38M 10-Q · filed 2019-11-14 | $35.74M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-06-30 | $15.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $23.38M 10-Q · filed 2019-08-14 | $35.74M derived: sum of 3 quarters · filed 2020-03-26 | $89.56M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-03-31 | $7.99M 10-Q · filed 2019-05-14 | $20.36M derived: sum of 2 quarters · filed 2020-03-26 | $74.17M derived: sum of 3 quarters · filed 2020-03-26 | $74.17M derived: sum of 4 quarters · filed 2020-03-26 |
| 2017-12-31 | $12.37M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $66.18M derived: sum of 2 quarters · filed 2020-03-26 | $66.18M derived: sum of 3 quarters · filed 2020-03-26 | $77.67M 10-K · filed 2020-03-26 |
| 2017-09-30 | $53.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $53.81M derived: sum of 2 quarters · filed 2018-11-14 | $65.30M 10-Q · filed 2018-11-14 | $67.15M derived: sum of 4 quarters · filed 2019-03-26 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $11.49M 10-Q · filed 2018-08-14 | $13.33M derived: sum of 3 quarters · filed 2019-03-26 | $17.65M derived: sum of 4 quarters · filed 2019-03-26 |
| 2017-03-31 | $11.49M 10-Q · filed 2018-05-15 | $13.33M derived: sum of 2 quarters · filed 2019-03-26 | $17.65M derived: sum of 3 quarters · filed 2019-03-26 | $29.58M derived: sum of 4 quarters · filed 2019-03-26 |
| 2016-12-31 | $1.84M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $6.17M derived: sum of 2 quarters · filed 2019-03-26 | $18.09M derived: sum of 3 quarters · filed 2019-03-26 | $28.09M 10-K · filed 2019-03-26 |
| 2016-09-30 | $4.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $16.25M derived: sum of 2 quarters · filed 2017-11-14 | $26.24M 10-Q · filed 2017-11-14 | $36.28M derived: sum of 4 quarters · filed 2018-03-20 |
| 2016-06-30 | $11.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $21.92M 10-Q · filed 2017-08-14 | $31.96M derived: sum of 3 quarters · filed 2018-03-20 | $46.44M derived: sum of 4 quarters · filed 2018-03-20 |
| 2016-03-31 | $9.99M 10-Q · filed 2017-05-11 | $20.03M derived: sum of 2 quarters · filed 2018-03-20 | $34.51M derived: sum of 3 quarters · filed 2018-03-20 | |
| 2015-12-31 | $10.04M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-20 | $24.52M derived: sum of 2 quarters · filed 2018-03-20 | $109.44M 10-K · filed 2018-03-20 | |
| 2015-09-30 | $14.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $99.41M 10-Q · filed 2016-11-14 | ||
| 2015-06-30 | $84.93M 10-Q · filed 2016-08-10 | |||
| 2014-12-31 | $5.40M 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |